// App-Quantinova.ai

AEP669 : Impact of imputation method on efficacy results from the phase 3 optimal study of oral octreotide capsules in adult patients with acromegaly

Researchers

Presenter

  • Susan Samson

Principal Investigators

  • Lisa Nachtigall

  • Maria Fleseriu

  • Murray Gordon

  • Mojca Jensterle

  • Atanaska Elenkova

  • Mark E Molitch

  • William Ludlam

  • Gary Patou

  • Asi Haviv

  • Nienke Biermasz

  • Peter Trainer

  • Christian J Strasburger

  • Laurence Kennedy

  • Shlomo Melmed

Medical Centers

  • Baylor College of Medicine, Houston, Texas, United States

  • MGH Neuroendocrine and Pituitary Center, Chestnut Hill, United States

  • Oregon Health and Science University, Portland, Oregon, United States

  • Nephrology, Allegheny General Hospital, Pittsburgh, United States

  • University Medical Centre Ljubljana, Ljubljana, Slovenia

  • Medical University Sofia, Sofia, Bulgaria

  • Northwestern University, Evanston, IL, United States

  • Chiasma, Waltham, United States

  • Leiden University Medical Centre, Leiden, Netherlands

  • The Christie NHS Foundation TRUST, Manchester, United Kingdom

  • Charite Campus Mitte, Berlin, Germany

  • Cleveland Clinic Foundation, Cleveland, Ohio, United States

  • Cedars Sinai Medical Center, Los Angeles, California, United States

Locations

  • United States

  • Slovenia

  • Bulgaria

  • Netherlands

  • United Kingdom

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

Disease

  • Acromegaly

Biomarkers

  • Insulin-like growth factor 1

Drug/Treatment

  • Oral octreotide

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved